A 3-minute video and quick-reference list of October's 7 FDA cancer approvals, with the biomarker and monitoring points nurses need for each.
|Articles|May 4, 2015
Jasmine Martin Discusses Oral Adherence
Author(s)Jasmine Martin
Jasmine Martin, Director, West Region Medical Science Liaison Team, Takeda Oncology, discusses oral adherence.
Advertisement
Jasmine Martin, Director, West Region Medical Science Liaison Team, Takeda Oncology, discusses oral adherence.
“If patients aren’t taking their drugs, then how do we know that the outcomes will be [the same as] what the clinical trial [outcomes] were?†Martin asks.
Advertisement
Related to this article
Oral vitamin C did not slow clonal growth in the phase 2 EVITA trial but was linked to longer survival.
Kathryn Shady, PhD, RN, OCN, discusses research on emotional dissonance and vicarious trauma among hematology/oncology nurses.
Ellery Palanuk, MSN, RN, CN-BN, explains how navigators rely on multidisciplinary teams and tumor boards as breast cancer treatment evolves.
At EONS 2026, a City of Hope nurse practitioner explains how shifting immunotherapy from infusion to injection can free nurse and chair time.
Oncology nurses play a key role guiding patients about AI breast cancer risk assessment tools, dynamic re-testing, and individualized screening plans.
Dana-Farber nurse practitioners outline ADC patient selection, sequencing, ILD surveillance, and patient education from JADPRO Live 2026.
Dr. Andrew Pecora on leading the first IV oncolytic virus trial, building a top-50 cancer center, and using AI to fix the cost of cancer care.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
October 2026 FDA Approvals: 7 Cancer Updates for Oncology Nurses
2
What Nurses Should Tell Patients About Vitamin C in CCUS and MDS
3
How Oncology Nurses Can Overcome Common Barriers to Research
4
Vicarious Trauma Affects Oncology Nurses in Every Care Setting
5